Amitriptyline Comprehensive Study by Application (Depression, Migraine, Insomnia, Rheumatic diseases), Form (Tablet, Liquid), Distribution (Online Pharmacy, Hospital Pharmacy, Generic Drug Store), Dose (10mg, 25mg, 50mg, 75mg, 100mg) Players and Region - Global Market Outlook to 2026

Amitriptyline Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Amitriptyline?
Amitriptyline is the tricyclic antidepressant and a derivative of dibenzocycloheptadiene, used for treating the symptoms of depression. Amitriptyline is in a class of medications called tricyclic antidepressants. The drug relives from the symptoms through showing positive effect of the central nervous system through increasing stimulating the release of synaptic concentration of neurotransmitters such as serotonin and norepinephrine, which help in maintaining the overall mental balance. These antidepressant have sedative effects and thus can be used to treat the insomnia and migraine.

The market study is broken down, by Application (Depression, Migraine, Insomnia and Rheumatic diseases) and major geographies with country level break-up.

The market is highly competitive due to presence of generic drug manufacturers Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis (Switzerland), Viatris Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Accord Healthcare (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Inc. (India), Par Pharmaceutical (United States), Dipharma Francis Srl (Italy), Torrent Pharmaceuticals Ltd. (India), Watson laboratories Inc. (United States), Egis Pharmaceuticals PLC (Hungary) and GLENMARK PHARMACEUTICALS LTD (India) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Amitriptyline market by Type, Application and Region.

On the basis of geography, the market of Amitriptyline has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Tablet will boost the Amitriptyline market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution , the sub-segment i.e. Online Pharmacy will boost the Amitriptyline market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dose, the sub-segment i.e. 10mg will boost the Amitriptyline market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In October 2017, the Zydus Cadila received approval from the United States Food and Drug Administration (USFDA) for the Amitriptyline hydrochloride tablets in the America. The Amitriptyline hydrochloride tablets are available in 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg strength.


Market Drivers
  • Growing prevalence of migraine
  • Availability of generic drugs at a cheaper cost

Opportunities
  • Increasing cases of life-style related stress and depression

Restraints
  • Side Effects of amitriptyline drugs


Key Target Audience
Generic drug manufacturers, Depression treatment drug companies, Research Institutes and Government

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Depression
  • Migraine
  • Insomnia
  • Rheumatic diseases
By Form
  • Tablet
  • Liquid

By Distribution
  • Online Pharmacy
  • Hospital Pharmacy
  • Generic Drug Store

By Dose
  • 10mg
  • 25mg
  • 50mg
  • 75mg
  • 100mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of migraine
      • 3.2.2. Availability of generic drugs at a cheaper cost
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Amitriptyline, by Application, Form, Distribution , Dose and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Amitriptyline (Value)
      • 5.2.1. Global Amitriptyline by: Application (Value)
        • 5.2.1.1. Depression
        • 5.2.1.2. Migraine
        • 5.2.1.3. Insomnia
        • 5.2.1.4. Rheumatic diseases
      • 5.2.2. Global Amitriptyline by: Form (Value)
        • 5.2.2.1. Tablet
        • 5.2.2.2. Liquid
      • 5.2.3. Global Amitriptyline by: Dose (Value)
        • 5.2.3.1. 10mg
        • 5.2.3.2. 25mg
        • 5.2.3.3. 50mg
        • 5.2.3.4. 75mg
        • 5.2.3.5. 100mg
      • 5.2.4. Global Amitriptyline Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Amitriptyline: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Viatris Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Accord Healthcare (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sun Pharmaceutical Industries Inc. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Par Pharmaceutical (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dipharma Francis Srl (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Torrent Pharmaceuticals Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Watson laboratories Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Egis Pharmaceuticals PLC (Hungary)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GLENMARK PHARMACEUTICALS LTD (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Amitriptyline Sale, by Application, Form, Distribution , Dose and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Amitriptyline (Value)
      • 7.2.1. Global Amitriptyline by: Application (Value)
        • 7.2.1.1. Depression
        • 7.2.1.2. Migraine
        • 7.2.1.3. Insomnia
        • 7.2.1.4. Rheumatic diseases
      • 7.2.2. Global Amitriptyline by: Form (Value)
        • 7.2.2.1. Tablet
        • 7.2.2.2. Liquid
      • 7.2.3. Global Amitriptyline by: Dose (Value)
        • 7.2.3.1. 10mg
        • 7.2.3.2. 25mg
        • 7.2.3.3. 50mg
        • 7.2.3.4. 75mg
        • 7.2.3.5. 100mg
      • 7.2.4. Global Amitriptyline Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Amitriptyline: by Application(USD Million)
  • Table 2. Amitriptyline Depression , by Region USD Million (2015-2020)
  • Table 3. Amitriptyline Migraine , by Region USD Million (2015-2020)
  • Table 4. Amitriptyline Insomnia , by Region USD Million (2015-2020)
  • Table 5. Amitriptyline Rheumatic diseases , by Region USD Million (2015-2020)
  • Table 6. Amitriptyline: by Form(USD Million)
  • Table 7. Amitriptyline Tablet , by Region USD Million (2015-2020)
  • Table 8. Amitriptyline Liquid , by Region USD Million (2015-2020)
  • Table 9. Amitriptyline: by Dose(USD Million)
  • Table 10. Amitriptyline 10mg , by Region USD Million (2015-2020)
  • Table 11. Amitriptyline 25mg , by Region USD Million (2015-2020)
  • Table 12. Amitriptyline 50mg , by Region USD Million (2015-2020)
  • Table 13. Amitriptyline 75mg , by Region USD Million (2015-2020)
  • Table 14. Amitriptyline 100mg , by Region USD Million (2015-2020)
  • Table 15. South America Amitriptyline, by Country USD Million (2015-2020)
  • Table 16. South America Amitriptyline, by Application USD Million (2015-2020)
  • Table 17. South America Amitriptyline, by Form USD Million (2015-2020)
  • Table 18. South America Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 19. South America Amitriptyline, by Dose USD Million (2015-2020)
  • Table 20. Brazil Amitriptyline, by Application USD Million (2015-2020)
  • Table 21. Brazil Amitriptyline, by Form USD Million (2015-2020)
  • Table 22. Brazil Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 23. Brazil Amitriptyline, by Dose USD Million (2015-2020)
  • Table 24. Argentina Amitriptyline, by Application USD Million (2015-2020)
  • Table 25. Argentina Amitriptyline, by Form USD Million (2015-2020)
  • Table 26. Argentina Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 27. Argentina Amitriptyline, by Dose USD Million (2015-2020)
  • Table 28. Rest of South America Amitriptyline, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Amitriptyline, by Form USD Million (2015-2020)
  • Table 30. Rest of South America Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 31. Rest of South America Amitriptyline, by Dose USD Million (2015-2020)
  • Table 32. Asia Pacific Amitriptyline, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Amitriptyline, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Amitriptyline, by Form USD Million (2015-2020)
  • Table 35. Asia Pacific Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 36. Asia Pacific Amitriptyline, by Dose USD Million (2015-2020)
  • Table 37. China Amitriptyline, by Application USD Million (2015-2020)
  • Table 38. China Amitriptyline, by Form USD Million (2015-2020)
  • Table 39. China Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 40. China Amitriptyline, by Dose USD Million (2015-2020)
  • Table 41. Japan Amitriptyline, by Application USD Million (2015-2020)
  • Table 42. Japan Amitriptyline, by Form USD Million (2015-2020)
  • Table 43. Japan Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 44. Japan Amitriptyline, by Dose USD Million (2015-2020)
  • Table 45. India Amitriptyline, by Application USD Million (2015-2020)
  • Table 46. India Amitriptyline, by Form USD Million (2015-2020)
  • Table 47. India Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 48. India Amitriptyline, by Dose USD Million (2015-2020)
  • Table 49. South Korea Amitriptyline, by Application USD Million (2015-2020)
  • Table 50. South Korea Amitriptyline, by Form USD Million (2015-2020)
  • Table 51. South Korea Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 52. South Korea Amitriptyline, by Dose USD Million (2015-2020)
  • Table 53. Taiwan Amitriptyline, by Application USD Million (2015-2020)
  • Table 54. Taiwan Amitriptyline, by Form USD Million (2015-2020)
  • Table 55. Taiwan Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 56. Taiwan Amitriptyline, by Dose USD Million (2015-2020)
  • Table 57. Australia Amitriptyline, by Application USD Million (2015-2020)
  • Table 58. Australia Amitriptyline, by Form USD Million (2015-2020)
  • Table 59. Australia Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 60. Australia Amitriptyline, by Dose USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Amitriptyline, by Application USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Amitriptyline, by Form USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Amitriptyline, by Dose USD Million (2015-2020)
  • Table 65. Europe Amitriptyline, by Country USD Million (2015-2020)
  • Table 66. Europe Amitriptyline, by Application USD Million (2015-2020)
  • Table 67. Europe Amitriptyline, by Form USD Million (2015-2020)
  • Table 68. Europe Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 69. Europe Amitriptyline, by Dose USD Million (2015-2020)
  • Table 70. Germany Amitriptyline, by Application USD Million (2015-2020)
  • Table 71. Germany Amitriptyline, by Form USD Million (2015-2020)
  • Table 72. Germany Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 73. Germany Amitriptyline, by Dose USD Million (2015-2020)
  • Table 74. France Amitriptyline, by Application USD Million (2015-2020)
  • Table 75. France Amitriptyline, by Form USD Million (2015-2020)
  • Table 76. France Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 77. France Amitriptyline, by Dose USD Million (2015-2020)
  • Table 78. Italy Amitriptyline, by Application USD Million (2015-2020)
  • Table 79. Italy Amitriptyline, by Form USD Million (2015-2020)
  • Table 80. Italy Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 81. Italy Amitriptyline, by Dose USD Million (2015-2020)
  • Table 82. United Kingdom Amitriptyline, by Application USD Million (2015-2020)
  • Table 83. United Kingdom Amitriptyline, by Form USD Million (2015-2020)
  • Table 84. United Kingdom Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 85. United Kingdom Amitriptyline, by Dose USD Million (2015-2020)
  • Table 86. Netherlands Amitriptyline, by Application USD Million (2015-2020)
  • Table 87. Netherlands Amitriptyline, by Form USD Million (2015-2020)
  • Table 88. Netherlands Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 89. Netherlands Amitriptyline, by Dose USD Million (2015-2020)
  • Table 90. Rest of Europe Amitriptyline, by Application USD Million (2015-2020)
  • Table 91. Rest of Europe Amitriptyline, by Form USD Million (2015-2020)
  • Table 92. Rest of Europe Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 93. Rest of Europe Amitriptyline, by Dose USD Million (2015-2020)
  • Table 94. MEA Amitriptyline, by Country USD Million (2015-2020)
  • Table 95. MEA Amitriptyline, by Application USD Million (2015-2020)
  • Table 96. MEA Amitriptyline, by Form USD Million (2015-2020)
  • Table 97. MEA Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 98. MEA Amitriptyline, by Dose USD Million (2015-2020)
  • Table 99. Middle East Amitriptyline, by Application USD Million (2015-2020)
  • Table 100. Middle East Amitriptyline, by Form USD Million (2015-2020)
  • Table 101. Middle East Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 102. Middle East Amitriptyline, by Dose USD Million (2015-2020)
  • Table 103. Africa Amitriptyline, by Application USD Million (2015-2020)
  • Table 104. Africa Amitriptyline, by Form USD Million (2015-2020)
  • Table 105. Africa Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 106. Africa Amitriptyline, by Dose USD Million (2015-2020)
  • Table 107. North America Amitriptyline, by Country USD Million (2015-2020)
  • Table 108. North America Amitriptyline, by Application USD Million (2015-2020)
  • Table 109. North America Amitriptyline, by Form USD Million (2015-2020)
  • Table 110. North America Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 111. North America Amitriptyline, by Dose USD Million (2015-2020)
  • Table 112. United States Amitriptyline, by Application USD Million (2015-2020)
  • Table 113. United States Amitriptyline, by Form USD Million (2015-2020)
  • Table 114. United States Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 115. United States Amitriptyline, by Dose USD Million (2015-2020)
  • Table 116. Canada Amitriptyline, by Application USD Million (2015-2020)
  • Table 117. Canada Amitriptyline, by Form USD Million (2015-2020)
  • Table 118. Canada Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 119. Canada Amitriptyline, by Dose USD Million (2015-2020)
  • Table 120. Mexico Amitriptyline, by Application USD Million (2015-2020)
  • Table 121. Mexico Amitriptyline, by Form USD Million (2015-2020)
  • Table 122. Mexico Amitriptyline, by Distribution USD Million (2015-2020)
  • Table 123. Mexico Amitriptyline, by Dose USD Million (2015-2020)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Amitriptyline: by Application(USD Million)
  • Table 137. Amitriptyline Depression , by Region USD Million (2021-2026)
  • Table 138. Amitriptyline Migraine , by Region USD Million (2021-2026)
  • Table 139. Amitriptyline Insomnia , by Region USD Million (2021-2026)
  • Table 140. Amitriptyline Rheumatic diseases , by Region USD Million (2021-2026)
  • Table 141. Amitriptyline: by Form(USD Million)
  • Table 142. Amitriptyline Tablet , by Region USD Million (2021-2026)
  • Table 143. Amitriptyline Liquid , by Region USD Million (2021-2026)
  • Table 144. Amitriptyline: by Dose(USD Million)
  • Table 145. Amitriptyline 10mg , by Region USD Million (2021-2026)
  • Table 146. Amitriptyline 25mg , by Region USD Million (2021-2026)
  • Table 147. Amitriptyline 50mg , by Region USD Million (2021-2026)
  • Table 148. Amitriptyline 75mg , by Region USD Million (2021-2026)
  • Table 149. Amitriptyline 100mg , by Region USD Million (2021-2026)
  • Table 150. South America Amitriptyline, by Country USD Million (2021-2026)
  • Table 151. South America Amitriptyline, by Application USD Million (2021-2026)
  • Table 152. South America Amitriptyline, by Form USD Million (2021-2026)
  • Table 153. South America Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 154. South America Amitriptyline, by Dose USD Million (2021-2026)
  • Table 155. Brazil Amitriptyline, by Application USD Million (2021-2026)
  • Table 156. Brazil Amitriptyline, by Form USD Million (2021-2026)
  • Table 157. Brazil Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 158. Brazil Amitriptyline, by Dose USD Million (2021-2026)
  • Table 159. Argentina Amitriptyline, by Application USD Million (2021-2026)
  • Table 160. Argentina Amitriptyline, by Form USD Million (2021-2026)
  • Table 161. Argentina Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 162. Argentina Amitriptyline, by Dose USD Million (2021-2026)
  • Table 163. Rest of South America Amitriptyline, by Application USD Million (2021-2026)
  • Table 164. Rest of South America Amitriptyline, by Form USD Million (2021-2026)
  • Table 165. Rest of South America Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 166. Rest of South America Amitriptyline, by Dose USD Million (2021-2026)
  • Table 167. Asia Pacific Amitriptyline, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific Amitriptyline, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Amitriptyline, by Form USD Million (2021-2026)
  • Table 170. Asia Pacific Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 171. Asia Pacific Amitriptyline, by Dose USD Million (2021-2026)
  • Table 172. China Amitriptyline, by Application USD Million (2021-2026)
  • Table 173. China Amitriptyline, by Form USD Million (2021-2026)
  • Table 174. China Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 175. China Amitriptyline, by Dose USD Million (2021-2026)
  • Table 176. Japan Amitriptyline, by Application USD Million (2021-2026)
  • Table 177. Japan Amitriptyline, by Form USD Million (2021-2026)
  • Table 178. Japan Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 179. Japan Amitriptyline, by Dose USD Million (2021-2026)
  • Table 180. India Amitriptyline, by Application USD Million (2021-2026)
  • Table 181. India Amitriptyline, by Form USD Million (2021-2026)
  • Table 182. India Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 183. India Amitriptyline, by Dose USD Million (2021-2026)
  • Table 184. South Korea Amitriptyline, by Application USD Million (2021-2026)
  • Table 185. South Korea Amitriptyline, by Form USD Million (2021-2026)
  • Table 186. South Korea Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 187. South Korea Amitriptyline, by Dose USD Million (2021-2026)
  • Table 188. Taiwan Amitriptyline, by Application USD Million (2021-2026)
  • Table 189. Taiwan Amitriptyline, by Form USD Million (2021-2026)
  • Table 190. Taiwan Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 191. Taiwan Amitriptyline, by Dose USD Million (2021-2026)
  • Table 192. Australia Amitriptyline, by Application USD Million (2021-2026)
  • Table 193. Australia Amitriptyline, by Form USD Million (2021-2026)
  • Table 194. Australia Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 195. Australia Amitriptyline, by Dose USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Amitriptyline, by Application USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Amitriptyline, by Form USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Amitriptyline, by Dose USD Million (2021-2026)
  • Table 200. Europe Amitriptyline, by Country USD Million (2021-2026)
  • Table 201. Europe Amitriptyline, by Application USD Million (2021-2026)
  • Table 202. Europe Amitriptyline, by Form USD Million (2021-2026)
  • Table 203. Europe Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 204. Europe Amitriptyline, by Dose USD Million (2021-2026)
  • Table 205. Germany Amitriptyline, by Application USD Million (2021-2026)
  • Table 206. Germany Amitriptyline, by Form USD Million (2021-2026)
  • Table 207. Germany Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 208. Germany Amitriptyline, by Dose USD Million (2021-2026)
  • Table 209. France Amitriptyline, by Application USD Million (2021-2026)
  • Table 210. France Amitriptyline, by Form USD Million (2021-2026)
  • Table 211. France Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 212. France Amitriptyline, by Dose USD Million (2021-2026)
  • Table 213. Italy Amitriptyline, by Application USD Million (2021-2026)
  • Table 214. Italy Amitriptyline, by Form USD Million (2021-2026)
  • Table 215. Italy Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 216. Italy Amitriptyline, by Dose USD Million (2021-2026)
  • Table 217. United Kingdom Amitriptyline, by Application USD Million (2021-2026)
  • Table 218. United Kingdom Amitriptyline, by Form USD Million (2021-2026)
  • Table 219. United Kingdom Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 220. United Kingdom Amitriptyline, by Dose USD Million (2021-2026)
  • Table 221. Netherlands Amitriptyline, by Application USD Million (2021-2026)
  • Table 222. Netherlands Amitriptyline, by Form USD Million (2021-2026)
  • Table 223. Netherlands Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 224. Netherlands Amitriptyline, by Dose USD Million (2021-2026)
  • Table 225. Rest of Europe Amitriptyline, by Application USD Million (2021-2026)
  • Table 226. Rest of Europe Amitriptyline, by Form USD Million (2021-2026)
  • Table 227. Rest of Europe Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 228. Rest of Europe Amitriptyline, by Dose USD Million (2021-2026)
  • Table 229. MEA Amitriptyline, by Country USD Million (2021-2026)
  • Table 230. MEA Amitriptyline, by Application USD Million (2021-2026)
  • Table 231. MEA Amitriptyline, by Form USD Million (2021-2026)
  • Table 232. MEA Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 233. MEA Amitriptyline, by Dose USD Million (2021-2026)
  • Table 234. Middle East Amitriptyline, by Application USD Million (2021-2026)
  • Table 235. Middle East Amitriptyline, by Form USD Million (2021-2026)
  • Table 236. Middle East Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 237. Middle East Amitriptyline, by Dose USD Million (2021-2026)
  • Table 238. Africa Amitriptyline, by Application USD Million (2021-2026)
  • Table 239. Africa Amitriptyline, by Form USD Million (2021-2026)
  • Table 240. Africa Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 241. Africa Amitriptyline, by Dose USD Million (2021-2026)
  • Table 242. North America Amitriptyline, by Country USD Million (2021-2026)
  • Table 243. North America Amitriptyline, by Application USD Million (2021-2026)
  • Table 244. North America Amitriptyline, by Form USD Million (2021-2026)
  • Table 245. North America Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 246. North America Amitriptyline, by Dose USD Million (2021-2026)
  • Table 247. United States Amitriptyline, by Application USD Million (2021-2026)
  • Table 248. United States Amitriptyline, by Form USD Million (2021-2026)
  • Table 249. United States Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 250. United States Amitriptyline, by Dose USD Million (2021-2026)
  • Table 251. Canada Amitriptyline, by Application USD Million (2021-2026)
  • Table 252. Canada Amitriptyline, by Form USD Million (2021-2026)
  • Table 253. Canada Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 254. Canada Amitriptyline, by Dose USD Million (2021-2026)
  • Table 255. Mexico Amitriptyline, by Application USD Million (2021-2026)
  • Table 256. Mexico Amitriptyline, by Form USD Million (2021-2026)
  • Table 257. Mexico Amitriptyline, by Distribution USD Million (2021-2026)
  • Table 258. Mexico Amitriptyline, by Dose USD Million (2021-2026)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Amitriptyline: by Application USD Million (2015-2020)
  • Figure 5. Global Amitriptyline: by Form USD Million (2015-2020)
  • Figure 6. Global Amitriptyline: by Dose USD Million (2015-2020)
  • Figure 7. South America Amitriptyline Share (%), by Country
  • Figure 8. Asia Pacific Amitriptyline Share (%), by Country
  • Figure 9. Europe Amitriptyline Share (%), by Country
  • Figure 10. MEA Amitriptyline Share (%), by Country
  • Figure 11. North America Amitriptyline Share (%), by Country
  • Figure 12. Global Amitriptyline share by Players 2020 (%)
  • Figure 13. Global Amitriptyline share by Players (Top 3) 2020(%)
  • Figure 14. Global Amitriptyline share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 18. Viatris Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Viatris Inc. (United States) Revenue: by Geography 2020
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 22. Accord Healthcare (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Accord Healthcare (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 26. Sun Pharmaceutical Industries Inc. (India) Revenue, Net Income and Gross profit
  • Figure 27. Sun Pharmaceutical Industries Inc. (India) Revenue: by Geography 2020
  • Figure 28. Par Pharmaceutical (United States) Revenue, Net Income and Gross profit
  • Figure 29. Par Pharmaceutical (United States) Revenue: by Geography 2020
  • Figure 30. Dipharma Francis Srl (Italy) Revenue, Net Income and Gross profit
  • Figure 31. Dipharma Francis Srl (Italy) Revenue: by Geography 2020
  • Figure 32. Torrent Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 33. Torrent Pharmaceuticals Ltd. (India) Revenue: by Geography 2020
  • Figure 34. Watson laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Watson laboratories Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Egis Pharmaceuticals PLC (Hungary) Revenue, Net Income and Gross profit
  • Figure 37. Egis Pharmaceuticals PLC (Hungary) Revenue: by Geography 2020
  • Figure 38. GLENMARK PHARMACEUTICALS LTD (India) Revenue, Net Income and Gross profit
  • Figure 39. GLENMARK PHARMACEUTICALS LTD (India) Revenue: by Geography 2020
  • Figure 40. Global Amitriptyline: by Application USD Million (2021-2026)
  • Figure 41. Global Amitriptyline: by Form USD Million (2021-2026)
  • Figure 42. Global Amitriptyline: by Dose USD Million (2021-2026)
  • Figure 43. South America Amitriptyline Share (%), by Country
  • Figure 44. Asia Pacific Amitriptyline Share (%), by Country
  • Figure 45. Europe Amitriptyline Share (%), by Country
  • Figure 46. MEA Amitriptyline Share (%), by Country
  • Figure 47. North America Amitriptyline Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis (Switzerland)
  • Viatris Inc. (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Accord Healthcare (United Kingdom)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sun Pharmaceutical Industries Inc. (India)
  • Par Pharmaceutical (United States)
  • Dipharma Francis Srl (Italy)
  • Torrent Pharmaceuticals Ltd. (India)
  • Watson laboratories Inc. (United States)
  • Egis Pharmaceuticals PLC (Hungary)
  • GLENMARK PHARMACEUTICALS LTD (India)
Select User Access Type

Key Highlights of Report


Feb 2021 232 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis (Switzerland), Viatris Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Accord Healthcare (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Inc. (India), Par Pharmaceutical (United States), Dipharma Francis Srl (Italy), Torrent Pharmaceuticals Ltd. (India), Watson laboratories Inc. (United States), Egis Pharmaceuticals PLC (Hungary) and GLENMARK PHARMACEUTICALS LTD (India) etc.
Analysts at AMA estimates Amitriptyline Market to reach USDXXX by 2026.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Amitriptyline Market Report?